BioNotebook: Seattle Genetics/AbbVie, Auspex, Flexion, Ironwood
This article was originally published in Scrip
Executive Summary
AbbVie extends Seattle Genetics collaboration; Auspex raises $35m; Flexion files for $86m IPO; and Ironwood makes 10% jobs cut.
You may also be interested in...
Seattle Genetics Looking To Improve, Replace Standards Of Care
Seattle Genetics is transitioning from a one-product to multi-product company while growing its established Adcetris franchise. New studies are coming for three additional antibody-drug conjugates aimed at solid tumors.
AbbVie Partnership On CD71 Gives CytomX Big Upfront, Co-Promotion Potential
Antibody-drug conjugates have taken a back seat to cancer immunotherapy as the hot modality in oncology of late, but AbbVie Inc. and CytomX Therapeutics Inc. unveiled a partnership on April 20 to develop an ADC in a deal that CytomX cites as further validation of its Probody technology platform.
Finance Watch: Dementia Discovery Fund’s Behr Sees Early Investments Reviving Neuroscience Interest
Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each.